Biogen (BIIB) Tops Q1 EPS by 6c; cuts guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $209.03 --0%
Revenue Growth %: -6.5%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 219.4M
Today's EPS Names:
CCEL, FNGR, FAST, More
Revenue Growth %: -6.5%
Financial Fact:
Diluted earnings per share attributable to Biogen Idec Inc.: 219.4M
Today's EPS Names:
CCEL, FNGR, FAST, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.02, $0.06 better than the analyst estimate of $2.96. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.23 billion.
GUIDANCE:
Biogen sees FY2025 EPS of $14.50-$15.50, versus the consensus of $15.20.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Biogen (BIIB)
- Truist on Occidental Petroleum (OXY): 'Expect Details Around LT FCF Improvement to Emerge'
- Susquehanna Upgrades CSX (CSX) to Positive
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
